Q4 2025 Marks Transition from Restructuring to Growth For 2026, Expects Double-Digit Revenue Growth, 400% Increase in CompuFlo Sales, and Continued Progress Toward Profitability ROSELAND, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the year ended December 31, 2025. Eric Hines, Chief Executive Offi ...

Core Insights - Milestone Scientific Inc. is undergoing a transformation aimed at strengthening its dental and medical businesses, reducing operating expenses, and positioning the company for accelerated growth and improved financial performance [1] Business Strategy - The new CEO, Eric Hines, has conducted a comprehensive review of operations and implemented strategic actions to accelerate growth, strengthen competitive position, and improve operating efficiency [2] - In the dental segment, the company is expanding North American sales programs, focusing on direct sales, enhancing omnichannel digital marketing, and securing new international registrations for the STA® Single Tooth Anesthesia System [2] - A similar strategy will be applied to the medical segment, including a guided relaunch of CompuFlo® and investment in market analysis and reimbursement strategies to maximize its commercial potential [2] Financial Performance - In the third quarter, the company reduced operating expenses by approximately 20% compared to the same period in 2024 while achieving modest revenue growth and an increase in recurring revenue from CompuFlo disposables [3] - There is strong international interest in CompuFlo, indicating potential for future growth [3] Future Outlook - The company is committed to advancing its innovative technology, expanding market presence, and executing on new products and partnerships [3] - The steps being taken are expected to provide a strong foundation for sustained growth and profitability [3]